|
Market Closed –
|
5-day change | 1st Jan Change | ||
|
434.05 DKK |
+0.47% | -8.44% | -30.46% | |
April 07, 2025 at 04:16 pm EDT
This article is reserved for members Unlock the article: REGISTER NOW!
© MT Newswires – 2025
|
Novo Nordisk to Invest $1.09 Billion in Brazil Production Expansion |
04:16pm |
MT |
|
Novo Nordisk to invest $1.09 billion to boost Ozempic, Wegovy production in Brazil |
04:04pm |
RE |
|
Novo Nordisk Considers Early Launch of Weight-Loss Jab Wegovy in India, Reuters Says, Citing Sources |
01:07pm |
DJ |
|
Novo preparing for early launch of weight-loss drug Wegovy in India |
11:29am |
RE |
|
Novo Nordisk to invest $1.09 billion to boost Ozempic, Wegovy production in Brazil |
11:14am |
RE |
|
European Equities Traded in the US as American Depositary Receipts Drop in Monday Trading |
11:10am |
MT |
|
Novo Nordisk to invest $1.09 billion to increase production in Brazil |
10:54am |
RE |
|
NOVO NORDISK : Bernstein reiterates its Neutral rating |
08:50am |
ZD |
|
NOVO NORDISK : Deutsche Bank reiterates its Buy rating |
07:30am |
ZD |
|
Trump administration drops Biden’s proposal of Medicare weight-loss drug coverage |
05:48am |
RE |
|
NOVO NORDISK : UBS reaffirms its Buy rating |
04:16am |
ZD |
|
Deutsche Bank lowers target price for Novo Nordisk to DKK 750 (900), reiterates Buy |
12:20am |
FW |
|
Trump administration drops Biden’s proposal of Medicare weight-loss drug coverage |
Apr. 04 |
RE |
|
Trump administration drops Biden’s proposal of Medicare weight-loss drug coverage |
Apr. 04 |
RE |
|
Stocks to Watch : Eli Lilly, Novo Nordisk, Hims & Hers, Maxeon Solar Technologies |
Apr. 04 |
DJ |
|
Shares of Obesity Drug Makers Lower, Proposal For Medicare Coverage Dropped |
Apr. 04 |
DJ |
|
NOVO NORDISK : Buy rating from UBS |
Apr. 04 |
ZD |
|
KKR drops out of consortium seeking Gerresheimer takeover, Bloomberg News reports |
Apr. 04 |
RE |
|
Jyske Bank lowers target price for Novo Nordisk to DKK 850 (925), reiterates Buy – BN |
Apr. 04 |
FW |
|
BP chair Lund to exit ‘likely’ in 2026 amid Elliott campaign |
Apr. 04 |
RE |
|
SEB lowers target price for Novo Nordisk to DKK 850 (1,000), reiterates Buy – BN |
Apr. 04 |
FW |
|
KKR drops out of consortium seeking Gerresheimer takeover, Bloomberg News reports |
Apr. 03 |
RE |
|
Novo Nordisk’s head of commercial strategy steps down |
Apr. 03 |
RE |
|
Global markets live: Tesla, Ford, Meta Platforms, Amazon, Siemens… |
Apr. 03 |
 |
|
Novo Nordisk Details Executive Management Changes |
Apr. 03 |
MT |
NOVO B: Dynamic Chart
Novo Nordisk A/S specializes in the design, manufacture and marketing of pharmaceutical products. Net sales break down by family of products as follows:
– diabetes and obesity treatment products (93.6%);
– rare disease treatment products (6.4%): intended for the treatment of haemophilia, blood disorders, hormonal disorders, etc.
Net sales are distributed geographically as follows: Europe/Middle East/Africa (20.8%), the United States (57.6%), North America (3.7%), China (6.4%) and other (11.5%).
More about the company
Buy
Last Close Price
432.00DKK
Average target price
771.37DKK
Spread / Average Target
+78.56%
Consensus
